Winners / 2023

VYVGART®

By: argenx
Silver

Master Category:

Award Category: Health, Medical & Biotech

Award Sub-Category: Treatment Optimization

VYVGARTⓇ (efgartigimod alfa-fcab) is a pioneering medicine filling an urgent unmet need for adults with generalized myasthenia gravis (gMG) who are AChR antibody positive. It’s the only approved FcRn blocker, establishing a new class of drugs, and the first approved therapy designed to reduce pathogenic IgGs, the driver of 100+ autoimmune diseases.

Explore more Energy & Sustainability

Put your innovation in the spotlight.

For four decades, the Edison Awards have recognized innovative products, services, and technologies that create meaningful value and impact. Explore the categories, find the right fit, and enter your new innovation for recognition.

Ready for Nomination Season?

Complete the form below to download the 2027 Nomination Guide.

A Founders Guide to Modern Innovation
The Future of the Grid – Panel Discussion 2024 Edison Awards
Edison Award-Winning Brain Technology Featured in U.S. News & World Report